CanFite is an advanced clinical stage drug development company with a platform oral drug technology designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. Its anti-inflammatory drug candidate, Piclidenoson, was found safe and effective in a Phase 3 trial for psoriasis . A pivotal Phase 3 psoriasis trial for market approval has been cleared by the European Medicines Agency (EMA) and is now under preparation. Can-Fite’s Namodenoson, for the treatment of cancer and liver diseases, is in a pivotal Phase 3 trial for advanced livercancer , a Phase 2b trial for the treatment NASH, and is expected to commence a Phase 2a exploratory study in pancreatic cancer. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date.
For more information, please visit their website.
Download the PPT here.
Corporate Speaker:
Pnina Fishman, Ph.D.
CEO
Prof. Fishman is the Scientific Founder of the Company and was previously a professor of Life Sciences and headed the Laboratory of Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center. Prof. Fishman is a very accomplished scientist and has authored or co-authored 170 publications and presented the findings of her research at many major scientific meetings. Her scientific work was the foundation on which Can-Fite was built. This scientific work has gained recognition as one of the leading approaches for next-generation therapies for cancer and other diseases. Her past managerial experience included seven years as CEO of Mor Research Application (MRA), a company that was in charge of the commercialization of intellectual property from all hospitals and research centers of Clalit Health Services, the largest healthcare provider in Israel, and was also the first clinical CRO in Israel. She was also involved in the establishment and served on the Board of Directors of several life sciences technology start-ups.
Disclaimer: NAI is being compensated for this content. Materials contained in this content are for information purposes only and is not intended to constitute an offering of securities in any jurisdiction. Nothing on this content should be construed as an offer, solicitation or recommendation to buy or sell products or securities.
